Firefly Dx successful in detecting MRSA

Firefly Dx polymerase chain reaction (PCR) device was able to identify samples of methicillin-resistant Staphylococcus aureus (MRSA) within a 20-minute timeframe during testing, the company announced Wednesday.

MRSA is an antibiotic-resistant infection that is often contracted within a hospital or other health care setting. Transparence Market Research reports the testing market for these kinds of infections is expected to increase with a compounded annual growth rate predicted at 19.3 percent up until 2019. According to research, the market is also expected to reach $7.5 billion by 2019.

The Firefly Dx system was designed to serve as a hand-held alternative to laboratory testing and identification

“We are excited by the continued positive results from the ongoing testing and development of our Firefly Dx prototype system,” PositiveID Corp. CEO and Chairman William Caragol said. “With the increasing prevalence of health care-associated infections and the increasing number of pathogens that are becoming drug-resistant, there is an important need for rapid, cost-effective testing solutions for hospital acquired disease testing.”

MRSA symptoms are often initially thought to be a spider bite, the U.S. Centers for Disease Control and Prevention states. Symptoms of MRSA include red and painful swelling on an area of the skin. The infection is usually accompanied by a fever, and if left untreated MRSA can spread to the bloodstream and lead to pneumonia.

Organizations in this Story

PositiveID Corporation

Want to get notified whenever we write about PositiveID Corporation ?
Next time we write about PositiveID Corporation, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.